Document is current
Any future updates will be listed below
-
Authors
Limbocker, Ryan
Mannini, Benedetta http://orcid.org/0000-0001-6812-7348
Ruggeri, Francesco S. http://orcid.org/0000-0002-1232-1907
Cascella, Roberta http://orcid.org/0000-0001-9856-6843
Xu, Catherine K.
Perni, Michele http://orcid.org/0000-0001-7593-8376
Chia, Sean
Chen, Serene W.
Habchi, Johnny
Bigi, Alessandra http://orcid.org/0000-0002-1067-6288
Kreiser, Ryan P.
Wright, Aidan K.
Albright, J. Alex
Kartanas, Tadas
Kumita, Janet R. http://orcid.org/0000-0002-3887-4964
Cremades, Nunilo http://orcid.org/0000-0002-9138-6687
Zasloff, Michael
Cecchi, Cristina http://orcid.org/0000-0001-8387-7737
Knowles, Tuomas P. J. http://orcid.org/0000-0002-7879-0140
Chiti, Fabrizio
Vendruscolo, Michele http://orcid.org/0000-0002-3616-1610
Dobson, Christopher M. http://orcid.org/0000-0002-5445-680X
-
Funding
Funding for this research was provided by:
Listed in manuscript for all authors.
- License Information
-
More Information
Article History
Received: 20 February 2020
Accepted: 7 July 2020
First Online: 13 August 2020
Competing interests
: M.Z. is one of the inventors in a patent for the use of trodusquemine in the treatment of Parkinson’s disease. C.M.D., M.V., T.P.J.K., and J.H. are co-founders and M.P. is an employee of Wren Therapeutics Ltd., which is independently pursuing inhibitors of protein misfolding and aggregation. The rest of the authors declare no competing interests.
